# PR104 and G-CSF in Treating Patients With Solid Tumors

> **NCT00616213** · PHASE1 · COMPLETED · sponsor: **Proacta, Incorporated** · enrollment: 5 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** PR104
- **OTHER:** F-18-fluoromisonidazole

## Key facts

- **NCT ID:** NCT00616213
- **Lead sponsor:** Proacta, Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-09
- **Final completion:** 2009-06
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2011-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00616213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00616213, "PR104 and G-CSF in Treating Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00616213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*